Sionna Therapeutics Other 8-K Filing
Sionna Therapeutics approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program, involving a 46% workforce reduction and the wind-down of its SION-719 add-on program. The company expects to incur approximately $6.4 million in restructuring charges, primarily for severance and contract close-out costs, while extending its cash runway into the second half of 2029. Additionally, Chief Business Officer Caroline Stark Beer was terminated without cause as part of the reorganization.
- Earnings call
- Sep 14, 2026, 4:30 PM ET